SMALL BIOEFFECTOR MOLECULES OF STREPTOCOCCUS MUTANS
变形链球菌的生物效应小分子
基本信息
- 批准号:2897165
- 负责人:
- 金额:$ 32.66万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1998
- 资助国家:美国
- 起止时间:1998-06-01 至 2002-05-31
- 项目状态:已结题
- 来源:
- 关键词:Streptococcus mutans antibiotics bacterial genetics bacterial proteins bacteriocin cell membrane gene expression mass spectrometry molecular cloning mutant northern blottings nuclear magnetic resonance spectroscopy nucleic acid sequence oral bacteria peptide structure pore forming protein protein biosynthesis protein purification protein structure function structural genes thin layer chromatography tissue /cell culture transcription factor
项目摘要
Streptococcus mutans strain JH1000 is a clinical isolate which has been
intensively studied because its superior ability to colonize the human
oral cavity makes it a logical choice for use in the replacement therapy
of dental caries. Mutant analysis was used to show that this stain's
colonization potential is dependent on its production of a small, highly
potent bacteriocin-like inhibitory substance (BLIS) that has a broad
antimicrobial spectrum of activity. Recent studies have proven that the
BLIS activity is a previously unidentified lantibiotic, which has been
named mutacin 1140. In the course of identifying this activity, we also
identified two N-acyl-L-homoserine lactone (AHSL)-like compounds, which
are molecules involved in quorum sensing in Gram negative bacteria and
which have not been previously described in Gram positive bacteria.
Preliminary evidence indicates that one or both of these compounds
positively regulates mutacin 1140 synthesis.
Certain studies proposed in this application are designed to elucidate
the structure, chemistry, and genetics of mutacin 1140 for its potential
application in replacement therapy and as an antibiotic and food
preservative. Other studies are designed to purify the AHSL-like
molecules to enable their precise and detailed structural
characterization. Physiology studies and mutant analysis will be used
to confirm their role in quorum sensing.
In specific aim 1 of this proposal, large scale purification methods
will be used to obtain sufficient mutacin 1140 to enable complete
structural identification using chemical methods and NMR spectroscopy.
In specific aim 2, the mechanism of action of mutacin 1140 on target
strains will be analyzed by determining its ability to form pores in
their cytoplasmic membranes. In specific aim 3, we will clone and
sequence all of the genes essential for mutacin 1140 synthesis and
determine their structural organization. Isogenic mutants will be
constructed and tested to determine the roles of the various genes in
mutacin 1140 synthesis. In specific aim 4, the optimum cultivation
conditions for AHSL synthesis will be determined and methods will be
developed to purify them to homogeneity. They will be structurally
characterized using spectroscopic methods. In specific aim 5, a
reporter gene-labeled construct of JH1140 will be mutagenized with Tn917
and mutants lacking positive regulators for mutacin 1140 expression will
be isolated and analyzed.
变形链球菌JH1000菌株是一株临床分离株
因为它优越的殖民能力而被深入研究
口腔使其成为替代疗法的合理选择
有很多龋齿。突变分析表明,该菌株的
殖民潜力取决于其产量小,高度
有效的细菌素样抑制物质(BLIS),具有广泛的
抗菌活性谱。最近的研究已经证明,
BLIS的活性是一种以前未被识别的抗生素,它已经被
命名为MUTACIN 1140。在确定这一活动的过程中,我们还
鉴定了两个N-酰基-L-高丝氨酸内酯类化合物
革兰氏阴性细菌中是否有参与群体感应的分子
以前在革兰氏阳性菌中没有描述过。
初步证据表明,这两种化合物中的一种或两种
正向调节突变蛋白1140的合成。
本申请中提出的某些研究旨在阐明
突变体1140的结构、化学和遗传学研究
在替代疗法中的应用以及作为抗生素和食品的应用
防腐剂。其他研究旨在提纯AHSL样蛋白
分子能够使其精确和详细的结构
人物刻画。将使用生理学研究和突变分析
以确认它们在群体感应中的作用。
在本提案的具体目标1中,大规模提纯方法
将用于获得足够的突变体1140以实现完全
用化学方法和核磁共振波谱进行结构鉴定。
在特定目标2中,突变体1140对靶点的作用机制
将通过确定其在体内形成气孔的能力来分析菌株
它们的细胞质膜。在具体目标3中,我们将克隆和
测定突变蛋白1140合成和合成所必需的所有基因的序列
确定它们的结构组织。同基因突变株将是
构建和测试以确定不同基因在
突变素1140的合成。在具体目标4上,优化栽培
将确定合成AHSL的条件和方法
开发的目的是将它们净化成同质。他们将在结构上
用光谱学方法进行了表征。在具体目标5中,a
Tn917诱变JH1140报告基因标记载体的研究
而缺乏突变体1140表达正调控因子的突变体将
被隔离和分析。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jeffrey D. Hillman其他文献
The Specific Pathogen-Free Human: a New Frontier in Oral Infectious Disease Research
无特定病原体的人类:口腔传染病研究的新领域
- DOI:
10.1177/08959374890030010501 - 发表时间:
1989 - 期刊:
- 影响因子:0
- 作者:
Martin A. Taubman;R. J. Genco;Jeffrey D. Hillman - 通讯作者:
Jeffrey D. Hillman
Jeffrey D. Hillman的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jeffrey D. Hillman', 18)}}的其他基金
Identification of Novel Genes Expressed in Bowel Cancer Using Change Mediated Ant
使用变化介导的蚂蚁鉴定肠癌中表达的新基因
- 批准号:
7266598 - 财政年份:2007
- 资助金额:
$ 32.66万 - 项目类别:
Genes of M. tuberculosis Induced During Human Infection
人类感染期间诱导的结核分枝杆菌基因
- 批准号:
6736413 - 财政年份:2004
- 资助金额:
$ 32.66万 - 项目类别:
SMALL BIOEFFECTOR MOLECULES OF STREPTOCOCCUS MUTANS
变形链球菌的生物效应小分子
- 批准号:
6176151 - 财政年份:1998
- 资助金额:
$ 32.66万 - 项目类别:
SMALL BIOEFFECTOR MOLECULES OF STREPTOCOCCUS MUTANS
变形链球菌的生物效应小分子
- 批准号:
2631568 - 财政年份:1998
- 资助金额:
$ 32.66万 - 项目类别:
SMALL BIOEFFECTOR MOLECULES OF STREPTOCOCCUS MUTANS
变形链球菌的生物效应小分子
- 批准号:
6379814 - 财政年份:1998
- 资助金额:
$ 32.66万 - 项目类别:
ISOLATION AND TESTING OF P GINGIVALIS VIRULENCE GENES
牙龈卟啉单胞菌毒力基因的分离与检测
- 批准号:
2132024 - 财政年份:1995
- 资助金额:
$ 32.66万 - 项目类别:
ISOLATION AND TESTING OF P GINGIVALIS VIRULENCE GENES
牙龈卟啉单胞菌毒力基因的分离与检测
- 批准号:
2132025 - 财政年份:1995
- 资助金额:
$ 32.66万 - 项目类别:
ISOLATION AND TESTING OF P GINGIVALIS VIRULENCE GENES
牙龈卟啉单胞菌毒力基因的分离与检测
- 批准号:
2443680 - 财政年份:1995
- 资助金额:
$ 32.66万 - 项目类别:
ISOLATION AND TESTING OF P GINGIVALIS VIRULENCE GENES
牙龈卟啉单胞菌毒力基因的分离与检测
- 批准号:
2733737 - 财政年份:1995
- 资助金额:
$ 32.66万 - 项目类别:
相似海外基金
Can antibiotics disrupt biogeochemical nitrogen cycling in the coastal ocean?
抗生素会破坏沿海海洋的生物地球化学氮循环吗?
- 批准号:
2902098 - 财政年份:2024
- 资助金额:
$ 32.66万 - 项目类别:
Studentship
The role of RNA repair in bacterial responses to translation-inhibiting antibiotics
RNA修复在细菌对翻译抑制抗生素的反应中的作用
- 批准号:
BB/Y004035/1 - 财政年份:2024
- 资助金额:
$ 32.66万 - 项目类别:
Research Grant
Metallo-Peptides: Arming Cyclic Peptide Antibiotics with New Weapons to Combat Antimicrobial Resistance
金属肽:用新武器武装环肽抗生素以对抗抗菌素耐药性
- 批准号:
EP/Z533026/1 - 财政年份:2024
- 资助金额:
$ 32.66万 - 项目类别:
Research Grant
Towards the sustainable discovery and development of new antibiotics
迈向新抗生素的可持续发现和开发
- 批准号:
FT230100468 - 财政年份:2024
- 资助金额:
$ 32.66万 - 项目类别:
ARC Future Fellowships
DYNBIOTICS - Understanding the dynamics of antibiotics transport in individual bacteria
DYNBIOTICS - 了解抗生素在单个细菌中转运的动态
- 批准号:
EP/Y023528/1 - 财政年份:2024
- 资助金额:
$ 32.66万 - 项目类别:
Research Grant
Engineering Streptomyces bacteria for the sustainable manufacture of antibiotics
工程化链霉菌用于抗生素的可持续生产
- 批准号:
BB/Y007611/1 - 财政年份:2024
- 资助金额:
$ 32.66万 - 项目类别:
Research Grant
The disulfide bond as a chemical tool in cyclic peptide antibiotics: engineering disulfide polymyxins and murepavadin
二硫键作为环肽抗生素的化学工具:工程化二硫多粘菌素和 murepavadin
- 批准号:
MR/Y033809/1 - 财政年份:2024
- 资助金额:
$ 32.66万 - 项目类别:
Research Grant
Role of phenotypic heterogeneity in mycobacterial persistence to antibiotics: Prospects for more effective treatment regimens
表型异质性在分枝杆菌对抗生素持久性中的作用:更有效治疗方案的前景
- 批准号:
494853 - 财政年份:2023
- 资助金额:
$ 32.66万 - 项目类别:
Operating Grants
Imbalance between cell biomass production and envelope biosynthesis underpins the bactericidal activity of cell wall -targeting antibiotics
细胞生物量产生和包膜生物合成之间的不平衡是细胞壁靶向抗生素杀菌活性的基础
- 批准号:
2884862 - 财政年份:2023
- 资助金额:
$ 32.66万 - 项目类别:
Studentship
Narrow spectrum antibiotics for the prevention and treatment of soft-rot plant disease
防治植物软腐病的窄谱抗生素
- 批准号:
2904356 - 财政年份:2023
- 资助金额:
$ 32.66万 - 项目类别:
Studentship














{{item.name}}会员




